Peptides for Traumatic Brain Injury: A Comprehensive Guide

Traumatic brain injury (TBI) affects an estimated 69 million people worldwide each year, ranging from mild concussions to severe injuries that result in permanent disability or death. Despite decades of research, no pharmaceutical treatment has achieved FDA approval specifically for TBI neuroprotection. Standard care remains largely supportive -- stabilizing the patient, managing intracranial pressure, and providing rehabilitation. This enormous unmet medical need has driven researchers to investigate peptide-based therapies that may intervene in the complex injury cascades that follow the initial trauma.

TBI Pathophysiology: Why Secondary Injury Is the Therapeutic Target

TBI involves two distinct phases of damage. The primary injury occurs at the moment of impact -- mechanical forces cause direct neuronal death, axonal shearing, and vascular disruption. This damage is, by definition, irreversible once it has occurred.

The secondary injury cascade unfolds over hours, days, and weeks following the initial trauma. This cascade includes several interconnected processes:

• Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6), amplifying tissue damage beyond the initial injury site.
• Excitotoxicity: Excessive glutamate release overstimulates NMDA and AMPA receptors, leading to calcium overload and neuronal death.
• Oxidative stress: Free radical production overwhelms endogenous antioxidant defenses, damaging lipids, proteins, and DNA.
• Blood-brain barrier (BBB) disruption: Breakdown of the BBB permits infiltration of peripheral immune cells and plasma proteins, worsening edema and inflammation.
• Cerebral edema: Swelling increases intracranial pressure, compressing healthy tissue and reducing perfusion.

Because the secondary cascade is progressive rather than instantaneous, it represents a window of therapeutic opportunity. Most peptide research for TBI targets one or more components of this cascade.

Cerebrolysin

Mechanism

Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight peptides and free amino acids. Its composition includes fragments with structural and functional similarities to endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). These peptide fragments are small enough to cross the blood-brain barrier, where they are thought to promote neuronal survival, synaptic plasticity, and neurogenesis while reducing neuroinflammation and excitotoxicity.

Clinical Evidence

Cerebrolysin is notable as one of the few peptide therapies with actual human clinical trial data in TBI. The CAPTAIN trial (Cerebrolysin and Recovery After Acute Brain Injury Requiring Intensive Care) was a randomized controlled trial examining its effects on moderate-to-severe TBI outcomes. Additional RCTs have evaluated cerebrolysin in TBI populations, generally reporting improvements in Glasgow Outcome Scale scores and cognitive recovery markers, though results have not been uniformly positive across all endpoints.

Clinical protocols have typically used doses of 30 to 50 mL administered intravenously daily for 10 or more consecutive days, initiated within the acute post-injury period. Cerebrolysin is approved for clinical use in several countries across Europe, Asia, and Latin America for brain injury and stroke indications. It is not FDA-approved in the United States, which limits its availability and reflects the reality that larger, confirmatory trials meeting Western regulatory standards are still needed.

Semax

Mechanism

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment. It does not retain the hormonal activity of full-length ACTH but instead exerts nootropic and neuroprotective effects through several pathways. Semax has been shown to upregulate the expression of BDNF and NGF in brain tissue, reduce pro-inflammatory cytokines including IL-1beta and TNF-alpha, and modulate glutamate signaling in ways that may attenuate excitotoxic damage.

Evidence

Semax is approved in Russia for clinical use in stroke and TBI and has been used in Russian clinical practice for several decades. However, the evidence base for semax presents a challenge for Western evaluation: much of the clinical literature is published in Russian-language journals and has not been replicated in international, multi-center trials that meet current Western regulatory standards.

The peptide is typically administered via the intranasal route, which offers the advantage of partial bypassing of the blood-brain barrier through direct nose-to-brain transport. While the preclinical data supporting semax's neuroprotective mechanisms is substantial and published in English-language journals, clinicians outside of Russia should recognize the limited availability of high-quality, peer-reviewed clinical trial data accessible to international scrutiny.

BPC-157

Mechanism

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Its proposed mechanisms relevant to brain injury include promotion of angiogenesis and vascular repair, modulation of the nitric oxide (NO) system, and direct neuroprotective effects observed in animal models of brain injury. BPC-157 has also demonstrated effects on the GI-brain axis, influencing dopaminergic and serotonergic pathways in preclinical models.

In animal studies of brain injury, BPC-157 has shown reductions in edema, improved neurological scores, and attenuation of BBB disruption. Its vascular repair properties may be particularly relevant given the role of microvascular damage in TBI pathophysiology.

Evidence

It is important to be direct: no human clinical trials exist for BPC-157 in TBI or any brain injury application. The entirety of the evidence for its neuroprotective effects comes from animal models. While these preclinical results are intriguing, the gap between rodent brain injury models and human TBI is substantial. Any claims about BPC-157's efficacy for TBI in humans are extrapolations from animal data, and should be understood as such.

Dihexa

Mechanism

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide designed as a hepatocyte growth factor (HGF) mimetic. HGF and its receptor c-Met play roles in neuronal survival, synaptogenesis, and dendritic spine formation. Dihexa has been shown to promote synaptogenesis and enhance dendritic spine density in animal models and is reported to cross the blood-brain barrier.

Evidence

Dihexa is the most speculative of the four peptides discussed here. The published evidence consists primarily of animal cognition studies demonstrating improvements in learning and memory tasks. There are no clinical trials, no established safety profile in humans, and no regulatory approval in any jurisdiction. Its inclusion in discussions of TBI peptides reflects theoretical interest based on its mechanism rather than any direct evidence of efficacy in brain injury.

Practical Considerations

For individuals and clinicians exploring peptide therapies in the context of TBI, several practical factors warrant attention:

• Timing: The secondary injury cascade begins within minutes and evolves over weeks. Earlier intervention during the acute and subacute phases is generally considered more likely to influence outcomes, though the optimal therapeutic windows for specific peptides remain poorly defined.
• Combination approaches: Given the multifactorial nature of secondary injury, some practitioners have explored using multiple peptides targeting different pathways. This approach lacks clinical trial support and introduces additional safety unknowns.
• Delivery routes: Intravenous (cerebrolysin), intranasal (semax), and subcutaneous or oral (BPC-157) routes each have different pharmacokinetic profiles and BBB penetration characteristics.
• Medical supervision: TBI management requires qualified medical professionals. Any peptide therapy should be considered only as a potential adjunct to, never a replacement for, standard neurological care.

Evidence Assessment

The evidence quality across these four peptides varies dramatically:

• Cerebrolysin: The strongest evidence base. Multiple randomized controlled trials in human TBI patients. Approved in several countries. Limitations include inconsistent results across endpoints and lack of FDA approval.
• Semax: Clinical use in Russia for decades with regulatory approval, but limited Western clinical data. Substantial preclinical evidence published in English-language journals.
• BPC-157: Entirely preclinical. Promising animal data but zero human trials for brain injury. The translation gap is significant.
• Dihexa: Experimental and early-stage. Animal cognition studies only. No established human safety profile.

Important Disclaimer

Traumatic brain injury is a medical emergency. Anyone who sustains a head injury with loss of consciousness, confusion, vomiting, seizures, or other neurological symptoms should seek emergency medical care immediately.

The peptides discussed in this article are not substitutes for emergency medical treatment, neurosurgical intervention, or standard TBI rehabilitation protocols. This content is provided for educational purposes only and does not constitute medical advice. The evidence for most peptide therapies in TBI ranges from limited to nonexistent in human clinical settings.

Individuals interested in peptide therapies for TBI recovery should consult with qualified healthcare providers -- ideally neurologists or physiatrists experienced in brain injury rehabilitation -- who can evaluate the potential risks and benefits in the context of their specific clinical situation. Self-treatment of brain injury with experimental peptides carries unknown risks and is strongly discouraged.